(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...

The biosimilars include Hyrimoz and an unbranded version of Humira from Swiss drugmaker Novartis' (NOVN.S), opens new tab Sandoz generics division, as well as German drugmaker Boehringer Ingelheim's ...

Cigna’s pharmacy benefit manager Express Scripts will put “multiple" biosimilar versions of Abbvie’s expensive rheumatoid arthritis drug Humira in the “same position as the brand” on the PBM’s as a ...

AbbVie is one of the largest global Pharmaceuticals, with a market cap of >$265bn. The company's lead asset - all-time best selling immunology drug Humira - finally loses patent protection this year ...

The arthritis drug Humira has been a blockbuster seller for more than two decades. Now, some copycats could end Humira's reign. The blockbuster drug Humira has been one of the world's top sellers for ...

If you’re one of the millions of Americans taking the prescription medication Humira, get ready to add the word biosimilars to your conversations with your doctor. Starting July 1, alternatives to the ...

(Reuters) - Drugmaker AbbVie and Icelandic biopharma company Alvotech have settled a legal fight over Alvotech's proposed generic version of AbbVie's blockbuster arthritis drug Humira, according to an ...

The maker of the blockbuster medication Humira created a “patent thicket” to illegally maintain a monopoly over the drug so it could be sold at an ever-increasing rate to the U.S. market, a major ...

Pharmaceutical giant AbbVie has agreed to a $24 million settlement that will require it to change its marketing practices for its immunology drug Humira, California Insurance Commissioner Ricardo Lara ...

(Reuters) - UnitedHealth Group said on Tuesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and ...

The maker of the blockbuster medication Humira created a “patent thicket” to illegally maintain a monopoly over the drug so it could be sold at an ever-increasing rate to the U.S. market, a major ...